19/06/2025
May 6–7, 2025 – SOLVE Annual Meeting in Madrid
May 6–7, 2025 – SOLVE Annual Meeting in Madrid
Building on the foundations laid during the Kick-Off Meeting in 2024, the SOLVE consortium reconvened in Madrid for its first Annual Meeting. Hosted on May 6–7, 2025, this fully in-person event brought together all project partners as well as members of the Scientific Advisory Board to review progress, provide recommendations and prepare for the next key phases of the project.
Tracking Progress, Refining Strategy
The meeting provided a timely opportunity to assess the advancements made across SOLVE’s nine Work Packages. Vaccine platforms have advanced significantly, with four candidates now in preclinical testing and early data showing promising immune responses. The Experimental Medicine Trial (EMT) protocol was updated to include a third clinical site and 60 participants, with regulatory submissions underway. Preparations are also complete for deep immunological profiling, data integration, and modeling.
Stakeholder research is progressing, with qualitative interviews and survey design helping to better understand public and healthcare professionals’ perceptions of COVID-19 vaccines. These insights will inform future communication strategies and support the development of more acceptable and trusted vaccine approaches.
Coordination, communication, and reporting activities are well structured, ensuring the project remains on track and aligned with its overall timeline.
Strengthening Collaboration for Impact
The Annual Meeting reaffirmed the project’s collaborative approach, with vibrant exchanges between scientists, clinicians, data scientists, and social researchers. The presence and input of the Scientific Advisory Board added valuable external perspectives, helping to guide the
consortium toward its next steps.
With continued progress, a reinforced roadmap, and strong collaboration across partners, SOLVE remains firmly on track to deliver on its mission: to develop next-generation vaccine platforms capable of tackling SARS-CoV-2 and its evolving variants.